Anti-β2GPI-antibody-induced endothelial cell gene expression profiling reveals induction of novel pro-inflammatory genes potentially involved in primary antiphospholipid syndrome

Annals of the Rheumatic Diseases

Volumn 66, Issue 8, 2007, Pages 1000-1007

  Hamid, C ^a,b   Norgate, K ^a   D'Cruz, D P ^c   Khamashta, M A ^c   Arno, M ^a   Pearson, J D ^a   Frampton, G ^b   Murphy, John J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

^c ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1; BETA2 GLYCOPROTEIN 1 ANTIBODY; CELL ADHESION MOLECULE; CHEMOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GROWTH FACTOR; IMMUNOGLOBULIN G; INTERLEUKIN 18 RECEPTOR ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; TRANSCRIPTION FACTOR; AUTOANTIBODY; INTERLEUKIN 8;

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN GENOME; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; UNINDEXED SEQUENCE; VASCULAR DISEASE; ADULT; ANTIGEN ANTIBODY REACTION; CASE CONTROL STUDY; DNA MICROARRAY; DOWN REGULATION; FEMALE; GENE EXPRESSION PROFILING; IMMUNOLOGY; MIDDLE AGED;

ADULT; ANTIGEN-ANTIBODY REACTIONS; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; BETA 2-GLYCOPROTEIN I; CASE-CONTROL STUDIES; DOWN-REGULATION; E-SELECTIN; ENDOTHELIAL CELLS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN-8; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 34547218488     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.063909     Document Type: Article

References (49)

1. Cameron JS, Frampton G. The antiphospholipid syndrome and the lupus anticoagulant. Pediatr Nephro 1990;4:663-78.
2. Roubey RAS. Immunology of the antiphospholipid antibody syndrome. Arthritis Rheum 1996;39:1444-54.
3. Blank M, Cohen J, Toder V, Shoenfeld Y. Induction of anti-phospholipid syndrome in naïve mice with lupus monoclonal and human polyclonal anticardiolipin antibodies. Proc Natl Acad Sci USA 1991;88:3069-73.
4. Ritchie DS, Sainani A, D'Souza A, Grigg AP. Passive donor-to-recipient transfer of antiphospholipid syndrome following allogeneic stem-cell transplantation. Am J Hematol 2005;79:299-302.
5. Del Papa N, Sheng Y H, Raschi E, Kandiah DA, Tincani A, Khamashta MA, et al. Human β2-glycoprotein I binds to endothelial cells through a cluster of lysine residues that are critical for anionic phospholipid binding and offers epitopes for anti-β2-glycoprotein I antibodies. J Immunol 1998;160:5572-78.
6. 2-Glycoprotein I reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome. Arthritis Rheum 1994;37:1453-61.
7. 2-glycoprotein I mediates the antibody binding to endothelial membranes and induces the expression of adhesion. Clin Exp Rheumatol 1995;13:179-85.
8. George J, Blank M, Levy Y, Meroni PL, Damianovich M, Tincani A, et al. Differential effects of anti-β2-glycoprotein I antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome. Circulation 1998;97:900-906.
9. Del Papa N, Guidali L, Sala A, Buccellati C, Khamashta MA, Ichikawa K, et al. Endothelial cells as target for antiphospholipid antibodies. Human polyclonal and monoclonal anti-β2-glycoprotein I antibodies react in vitro with endothelial cells through adherent β2-glycoprotein I and induce endothelial activation. Arthritis Rheum 1997;40:551-61.
10. Meroni P, Ronda N, Raschi E, Borghi MO. Humoral autoimmunity against endothelium: theory or reality? Trends Immunol 2005;26:275-81.
11. Pierangeli SS, Colden-Stanfield M, Liu X, Barker JH, Anderson GL, Harris EN. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 1999;99:1997-02.
12. Simantov R, LaSala JM, Lo SK, Gharavi AE, Sammaritano LR, Salmon JE, et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995;96:2211-19.
13. Pierangeli SS, Gharavi AE, Harris EN. Experimental thrombosis and antiphospholipid antibodies: new insights. J Autoimmun 2000;15:241-47.
14. Dunoyer-Geindre S, de Moerloose P, Galve-de Rochemonteix B, Reber G, Kruithof EK. NFkappaB is an essential intermediate in the activation of endothelial cells by anti-β(2)-glycoprotein I antibodies. Thromb Haemost 2002;88:851-7.
15. Raschi E, Testoni C, Bosisio D, Borghi MO, Koike T, Mantovani A, et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 2003;101:3495-00.
16. Bohgaki M, Atsumi T, Yamashita Y, Yasuda S, Sakai Y, Furusaki A, et al. The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-β2glycoprotein I antibodies. Int Immunol 2004;16:1633-41.
17. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999;42:1309-11.
18. Wang MX, Kandiah DA, Ichikawa K, Khamashta MA, Hughes G, Koike T, et al. Epitope specificity of monoclonal anti-β2-glycoprotein I antibodies derived from patients with the antiphospholipid syndrome. J Immunol 1995;155:1629-1636.
19. Harris EN, Gharavi AE, Patel SP, Hughes GR. Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol 1987;68:215-22.
20. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973;52:2745-53.
21. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc Ser B (Methodological) 1995;57:289-00.
22. Bustin SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reactions assays. J Mol Endocrin 2000;25:169-93.
23. Stone S, Pijnenborg R, Vercruysse L, Poston R, Khamashta MA, Hunt BJ, et al. The placental bed in pregnancies complicated by primary antiphospholipid syndrome. Placenta 2006;27:457-467.
24. Girardi G, Berman J, Redecha P, Spruce L, Thurman JM, Kraus D, et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003;112:1644-1654.
25. 3CL1). Circulation 2003;108:2498-504.
26. Teupser D, Pavlides S, Tan M, Gutierrez-Ramos J-C, Kolbeck R, Breslow JL. Major reduction of atherosclerosis in fractalkine (CX3CL1)-deficient mice is at the brachiocephalic artery, not the aortic root. PNAS 2004;101:17795-800.
27. Matsuura E, Kobayashi K, Yasuda T, Koike T. Antiphospholipid antibodies and atherosclerosis. Lupus 1998;7:S135-S139.
28. Matsuura E, Koike T. Accelerated atheroma and anti-β2- glycoprotein I antibodies. Lupus 2000;9:210-16.
29. George J, Harats D, Gilburd B, Afek A, Levy Y, Schneiderman J, et al. Immunolocalization of β2-glycoprotein i (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation 1999;99:2227-30.
30. Mallat Z, Corbaz A, Scoazec A, Besnard S, Leseche G, Chvatchko Y, et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 2001;104:1598-603.
31. Gerdes N, Sukhova GK, Libby P, Reynolds RS, Young JL, Schonbeck U. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med 2002;195:245-57.
32. Kume N, Murase T, Moriwaki H, Aoyama T, Sawamura T, Masaki T, et al. Inducible expression of lectin-like oxidized LDL receptor-1 in vascular endothelial cells. Circ Res 1998;833:322-327.
33. Mango R, Clementi F, Borgiani P, Forleo GB, Federici M, Contino G, et al. Association of single nucleotide polymorphisms in the oxidized LDL receptor 1 (OLR1) gene in patients with acute myocardial infarction. J Med Genet 2003;40:933-936.
34. Hasunuma Y, Matsuura E, Makita Z, Katahira T, Nishi S, Koike T. Involvement of β2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 1997;107(3):569-573.
35. Boerma M, Forsberg L, Van Zeijl L, Morgenstern R, De Faire U, Lemne C, et al. A genetic polymorphism in connexin 37 as a prognostic marker for atherosclerotic plaque development. J Intern Med 1999;246:211-8.
36. Cuadrado MJ, Lopez-Pedrera C, Khamashta MA, Camps MT, Tinahones F, Torres A, et al. Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression. Arthritis Rheum 1997;40:834-41.
37. Kornberg A, Blank M, Kaufman S, Shoenfeld Y. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol 1994;153:1328-32.
38. Lopez-Pedrera CH, Buendia P, Aguirre MA, Velasco F, Cuadrado MJ. Antiphospholipid syndrome and tissue factor: a thrombotic couple. Lupus 2006;15:161-6.
39. Frampton G, Hicks J, Cameron JS. Significance of anti-phospholipid antibodies in patients with lupus nephritis. Kidney Int 1991;39:1225-31.
40. Nesher G, Ilany J, Rosenmann D, Abraham AS. Valvular dysfunction in antiphospholipid syndrome: prevalence, clinical features, and treatment. Semin Arthritis Rheum 1997;27:27-35.
41. Nochy D, Daugas E, Droz D, Beaufils H, Grunfeld JP, Piette JC, et al. The intrarenal vascular lesions associated with primary antiphospholipid syndrome. J Am Soc Nephrol 1999;10:507-18.
42. 2 glycoprotein I antibodies. Blood 2005;105:1964-9.
43. Chung CY, Murphy-Ullrich JE, Erickson HP. Mitogenesis, cell migration, and loss of focal adhesions induced by tenascin-C interacting with its cell surface receptor, annexin II. Mol Biol Cell 1996;7:883- 92.
44. Zhao B, Bowden RA, Stavchansky SA, Bowman PD. Human endothelial cell response to gram-negative lipopolysaccharide assessed with cDNA microarrays. Am J Physiol Cell Physiol 2001;281:1587-95.
45. Zhao B, Stavchansky SA, Bowden RA, Bowman PD. Effect of interleukin-1β and tumour necrosis factor-α on gene expression in human endothelial cells. Am J Physiol Cell Physiol 2003;284:1577- 83.
46. Mayer H, Bilban M, Kurtev V, Gruber F, Wagner O, Binder BR, et al. Deciphering regulatory patterns of inflammatory gene expression from interleukin-1-stimulated human endothelial cells. Arterioscler Thromb Vasc Biol 2004;24:1192-8.
47. Meroni PL, Borghi MO, Raschi E, Ventura D, Sarzi Puttini PC, Atzeni F, et al. Inflammatory response and the endothelium. Throm Res 2004;114:329-34.
48. Forastiero RR, Martinuzzo ME, de Larrañaga GF. Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprosy related antiphospholipid antibodies. Lupus 2005;14:129-36.
49. Kaplanski G, Cacoub P, Farnarier C, Marin V, Gregoire R, Gatel A, et al. Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome: correlations with the severity of thrombosis. Arthritis Rheum 2000;43:55-64.